Market Exclusive

Analyst Activity – Cann Reiterates Hold on Clovis Oncology (NASDAQ:CLVS)

Analyst Ratings For Clovis Oncology (NASDAQ:CLVS)

Today, Cann reiterated its Hold rating on Clovis Oncology (NASDAQ:CLVS).

There are 6 hold ratings, 10 buy ratings on the stock.

The current consensus rating on Clovis Oncology (NASDAQ:CLVS) is Buy (Score: 2.63) with a consensus target price of $79.50 per share, a potential 18.89% downside.

Some recent analyst ratings include

Recent Insider Trading Activity For Clovis Oncology (NASDAQ:CLVS)
Clovis Oncology (NASDAQ:CLVS) has insider ownership of 17.40% and institutional ownership of 90.01%.

Recent Trading Activity for Clovis Oncology (NASDAQ:CLVS)
Shares of Clovis Oncology closed the previous trading session at 88.65 down -9.37 -9.56% with 2,366,057 shares trading hands.

Exit mobile version